Cite
HARVARD Citation
Ferrante, M. et al. (2019). OWE-05 Interim long-term safety/efficacy of risankizumab treatment in crohn's disease patients from the open-label extension study. Gut. 68 (2), p. A64. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Ferrante, M. et al. (2019). OWE-05 Interim long-term safety/efficacy of risankizumab treatment in crohn's disease patients from the open-label extension study. Gut. 68 (2), p. A64. [Online].